Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) Q2 2025 Earnings | 08/06/2025

About this video

Day One Biopharmaceuticals, Inc. reported strong second quarter 2025 financial results, highlighted by impressive revenue growth driven mainly by its flagship product OJEMDA. The company achieved net product revenue of $33.6 million for Q2 2025, marking a 310% increase compared to the same quarter last year. This significant growth was driven primarily by U.S. OJEMDA sales, underscoring the product's expanding market penetration. Earnings per share (EPS) came in at a loss of $0.29, better than the expected loss of $0.35, reflecting improved operating performance despite ongoing investments in commercialization and R&D. While revenue slightly missed some analyst projections, the overall growth trajectory and product adoption have impressed investors. Day One reiterated its full-year 2025 revenue guidance of $140 million to $150 million in total net revenues, signaling confidence in continued solid sales momentum and market expansion throughout the year. Operational highlights included strong uptake in key markets, ongoing clinical development programs, and strategic initiatives to boost market access and product awareness. The company remains focused on expanding its footprint in dermatology and advancing its pipeline to sustain long-term growth. About Inside Ticker: For more expert analysis and real-time updates on Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) and other market movers, follow Inside Ticker and visit InsideTicker.com for comprehensive reports, financial insights, and the latest news on leading companies. #DayOne #DAWN #Q22025 #Earnings #FinancialResults #RevenueGrowth #OJEMDA #Dermatology #Biopharma #NetLoss #EPS #ClinicalDevelopment #Guidance #Innovation #R&D #Commercialization #InsideTicker #2025Outlook #NASDAQ #InvestorUpdate